Epidemiological features of patients infected with hcv genotype 4 in poland

Hepatitis Monthly

Volumn 11, Issue 3, 2011, Pages 191-194

  Chlabicz, Slawomir ^a   Flisiak, Robert ^a   Lapinski, Tadeusz W ^a   Kowalczuk, Oksana ^a   Wiercinska Drapalo, Alicja ^a   Pytel Krolczuk, Barbara ^a   Grzeszczuk, Anna ^a   Chyczewski, Lech ^a   Pancewicz, Joanna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Genotypes hepatitis c drug users

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POLAND; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

EID: 79955603049     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74(Pt 11):2391-9.
2. Kamal SM. Improving outcome in patients with hepatitis C virus genotype 4. Am J Gastroenterol. 2007;102(11):2582-8.
3. Attia MA. Prevalence of hepatitis B and C in Egypt and Africa. Antivir Ther. 1998;3(Suppl 3):1-9.
4. Aguilera A, Losada E, Novoa S, Seoane R, Otero L, Gonzalez-Quintela A, et al. High prevalence of infection by hepatitis C virus genotype 4 in northern spain intravenous drug users with HIV infection. Antivir Ther. 2003;8(suppl 1):abstract no. 957.
5. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard- Hubert I, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat. 2005; (4):405-13.
6. Ramos B, Nunez M, Toro C, Sheldon J, Garcia-Samaniego J, Rios P, et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect. 2007;54(2):173-9.
7. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat. 2007;14(7):460-7.
8. Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int. 2009;29(Suppl 1):39-48.
9. Abdel-Hamid M, El-Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol. 2007;88(Pt 5):1526-31.
10. Chlabicz S, Flisiak R, Kowalczuk O, Grzeszczuk A, Pytel-Krolczuk B, Prokopowicz D, et al. Changing HCV genotypes distribution in Poland--relation to source and time of infection. J Clin Virol. 2008;42(2):156-9.
11. Chlabicz S, Flisiak R, Kowalczuk O, Wiercinska-Drapalo A, Pytel-Krolczuk B, Prokopowicz D, et al. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland. J Med Virol. 2008;80(4):615-8.
12. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol. 2004;38(1):68-71.
13. Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver. 2000;20(4):335-9.
14. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292(23):2839-48.
15. Maieron A, Metz-Gercek S, Hackl F, Luger C, Ziachehabi A, Strauss R, et al. Chronic hepatitis C in Austria, 1992-2006: genotype distribution and demographic factors. Euro Surveill. 2010;15(8):19492.
16. Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, et al. Heterogeneity of hepatitis C virus genotype 4 strainscirculating in south-western France. J Gen Virol. 2005;86(Pt 1):107-14.
17. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat. 2006;13(1):19-27.
18. Stanczak JJ, Opoka-Kegler J, Czerwionka-Szaflarska M, Karczewska K, Wozniakowska-Gesicka T, Horban A. Distribution of hepatitis C virus genotypes in Poland. J Hepatol. 1999;31(3):574.
19. Lapinski TW, Pawluczuk P, Flisiak R. Epidemiological and clinical characteristics of genotype 4 HCV infection in the north-east Poland. Przegl Epidemiol. 2009;63(4):501-4.
20. Raghuraman S, Abraham P, Sridharan G, Daniel HD, Ramakrishna BS, Shaji RV. HCV genotype 4-an emerging threat as a cause of chronic liver disease in Indian (south) patients. J Clin Virol. 2004;31(4):253-8.
21. Hayashi K, Fukuda Y, Nakano I, Katano Y, Toyoda H, Yokozaki S, et al. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatol Res. 2003;25(4):409-14.
22. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology. 2008;47(4):1371-83.
23. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30(3):342-55.